HC Wainwright Issues Optimistic Forecast for ELDN Earnings

Key Points

• HC Wainwright has revised its earnings per share estimate for Eledon Pharmaceuticals for Q3 2025 to ($0.18), an improvement from the previous estimate of ($0.31), maintaining a "Buy" rating and a target price of $9.00.
• Eledon Pharmaceuticals recently reported Q2 earnings of ($0.13) EPS, surpassing the consensus estimate of ($0.23), indicating potential positive momentum for the company.
• Several hedge funds significantly increased their stakes in Eledon, with Bank of America Corp DE growing its holdings by 261.8% in Q2, reflecting growing institutional interest in the stock.

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Research analysts at HC Wainwright upped their Q3 2025 earnings per share estimates for Eledon Pharmaceuticals in a research report issued to clients and investors on Tuesday, September 2nd. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.18) for the quarter, up from their previous forecast of ($0.31). HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Eledon Pharmaceuticals' Q4 2025 earnings at ($0.18) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.30) EPS and FY2026 earnings at ($1.31) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.10.

Several other research firms have also recently issued reports on ELDN. Zacks Research cut Eledon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 18th. Craig Hallum assumed coverage on Eledon Pharmaceuticals in a research report on Friday, July 25th. They set a "buy" rating and a $12.00 target price for the company. Finally, Wall Street Zen cut Eledon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, June 6th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Eledon Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $10.00.

Eledon Pharmaceuticals Stock Up 1.6%

NASDAQ ELDN opened at $2.59 on Thursday. The stock's 50-day moving average price is $3.05 and its 200-day moving average price is $3.20. Eledon Pharmaceuticals has a 52 week low of $2.38 and a 52 week high of $5.54. The company has a market capitalization of $155.09 million, a P/E ratio of -2.21 and a beta of -0.12.

Hedge Funds Weigh In On Eledon Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its holdings in Eledon Pharmaceuticals by 261.8% during the 2nd quarter. Bank of America Corp DE now owns 25,367 shares of the company's stock valued at $69,000 after buying an additional 18,355 shares in the last quarter. First Light Asset Management LLC grew its holdings in Eledon Pharmaceuticals by 11.7% during the 2nd quarter. First Light Asset Management LLC now owns 2,600,498 shares of the company's stock valued at $7,047,000 after buying an additional 271,730 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Eledon Pharmaceuticals during the 2nd quarter valued at approximately $87,000. Velan Capital Investment Management LP grew its holdings in Eledon Pharmaceuticals by 4.6% during the 2nd quarter. Velan Capital Investment Management LP now owns 338,973 shares of the company's stock valued at $919,000 after buying an additional 15,000 shares in the last quarter. Finally, Marshall Wace LLP grew its holdings in Eledon Pharmaceuticals by 393.6% during the 2nd quarter. Marshall Wace LLP now owns 94,772 shares of the company's stock valued at $257,000 after buying an additional 75,572 shares in the last quarter. Hedge funds and other institutional investors own 56.77% of the company's stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.